|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2003-10-28
|
|
pubmed:abstractText |
This study was conducted to assess the antitumour activity of docetaxel in combination with doxorubicin for neoadjuvant therapy of patients with breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BachelotTT,
pubmed-author:BendahmaneBB,
pubmed-author:CombeMM,
pubmed-author:De YbarluceaL RLR,
pubmed-author:DierasVV,
pubmed-author:FumoleauPP,
pubmed-author:GanemGG,
pubmed-author:LotzVV,
pubmed-author:MissetJ-LJL,
pubmed-author:Tubiana-HulinMM,
pubmed-author:VannetzelJ-MJM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1623-8
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:14581269-Adult,
pubmed-meshheading:14581269-Antibiotics, Antineoplastic,
pubmed-meshheading:14581269-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:14581269-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:14581269-Breast Neoplasms,
pubmed-meshheading:14581269-Carcinoma, Ductal, Breast,
pubmed-meshheading:14581269-Chemotherapy, Adjuvant,
pubmed-meshheading:14581269-Dose-Response Relationship, Drug,
pubmed-meshheading:14581269-Doxorubicin,
pubmed-meshheading:14581269-Female,
pubmed-meshheading:14581269-Humans,
pubmed-meshheading:14581269-Middle Aged,
pubmed-meshheading:14581269-Neoadjuvant Therapy,
pubmed-meshheading:14581269-Survival Analysis,
pubmed-meshheading:14581269-Taxoids,
pubmed-meshheading:14581269-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
|
|
pubmed:affiliation |
Centre Jean Bernard, Le Mans, France. gganem@noos.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
